Q2 2024 Avanos Medical Inc Earnings Call Transcript
Key Points
- Avanos Medical Inc (AVNS) reported strong performance in its Digestive Health portfolio, with organic growth of almost 9% year-over-year.
- The NeoMed product line posted double-digit growth, driven by strong demand for ENFit conversions in North America.
- The company's pain management and recovery portfolio showed positive momentum, with the combined on-Q and ambIT portfolio growing by mid-single digits.
- Avanos Medical Inc (AVNS) achieved a 17% year-over-year growth in adjusted EBITDA, with a margin expansion of 210 basis points.
- The company maintained a strong balance sheet with $92 million in cash and a conservative leverage level of less than one times.
- The HA portfolio experienced a significant decline, down more than 30% year-over-year, impacting overall revenue growth.
- Despite improvements, the surgical pain portfolio was down slightly year-over-year, indicating challenges in this segment.
- The company anticipates lower growth for the NeoMed product line in the coming quarters as ENFit conversion adoption reaches later stages.
- Free cash flow expectations for 2024 were adjusted downward due to higher one-time charges and inventory levels.
- Avanos Medical Inc (AVNS) faced challenges in executing M&A opportunities, with some deals not proceeding due to pricing and technology concerns.
Good morning, ladies and gentlemen, and welcome to the Avanos Medical Q2 2024 earnings call. (Operator Instructions) This call is being recorded on Wednesday, July 31, 2024.
I would now like to turn the conference over to Scott Galovan, Senior Vice President, Strategy and Corporate Development. Please go ahead.
Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to Avanos 2024 second quarter earnings conference call. Presenting today will be Joe Woody, CEO; and Michael Greiner, Senior Vice President, CFO and Chief Transformation Officer. Joe will review our second quarter results and current business environment, as well as provide an update on our transformation efforts. Michael will share additional details regarding these topics and affirm our 2024 planning assumptions. We'll finish the call with Q&A. A the presentation for today's call is available on the Investors section of our website, avanos.com.
As a reminder, our comments
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
